SCOPUS 정보 검색 플랫폼

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1624-1626

A novel agent effective against Clostridium difficile infection

(6) Dvoskin, Sofya a Xu, Wei Chu a Brown, Neal C a Yanachkov, Ivan B a Yanachkova, Milka a Wright, George E a

a GLSYNTHESIS INC (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DNA POLYMERASE; METRONIDAZOLE; N2 (3,4 DICHLOROBENZYL) 7 [2 (1 MORPHOLINYL)ETHYL]GUANINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONTROLLED STUDY; DNA REPLICATION; FEMALE; HAMSTER; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CRICETINAE; DISEASE MODELS, ANIMAL; DNA-DIRECTED DNA POLYMERASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MORPHOLINES; PURINES; VANCOMYCIN;

EID: 84863419874 PISSN: 00664804 EISSN: 10986596 Source Type: Journal
DOI: 10.1128/AAC.06097-11 Document Type: Article

Times cited : (17)

References (11)

1
- 84863394993
- Fidaxomicin
- doi:10.2165/ 11537730
- Adis. 2010. Fidaxomicin. Adis R&D profile. 10:37-45. doi:10.2165/ 11537730.
- (2010) Adis R&D Profile , vol.10 , pp. 37-45
- Adis¹

2
- 46249099130
- Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
- DOI 10.1128/AAC.00090-08
- Al-Nassir WN, et al. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci dur-ing treatment of Clostridium difficile-associated disease. Antimicrob. Agents Chemother. 52:2403-2406. (Pubitemid 351915669)
- (2008) Antimicrobial Agents and Chemotherapy , vol.52 , Issue.7 , pp. 2403-2406
- Al-Nassir, W.N.¹ Sethi, A.K.² Li, Y.³ Pultz, M.J.⁴ Riggs, M.M.⁵ Donskey, C.J.⁶

3
- 46249102186
- Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin
- DOI 10.1086/588293
- Al-Nassir WN, et al. 2008. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin. Infect. Dis. 47:56-62. (Pubitemid 351920588)
- (2008) Clinical Infectious Diseases , vol.47 , Issue.1 , pp. 56-62
- Al-Nassir, W.N.¹ Sethi, A.K.² Nerandzic, M.M.³ Bobulsky, G.S.⁴ Jump, R.L.P.⁵ Donskey, C.J.⁶

4
- 85036521989
- Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard
- Clinical and Laboratory Standards Institute. 7th ed. CLSI, Wayne, PA
- Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 7th ed. CLSI document M11-A7. CLSI, Wayne, PA.
- (2007) CLSI Document M11-A7

5
- 0031926083
- Clostridium difficile-associated diarrhea
- Johnson S, Gerding DN. 1998. Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 26:1027-1036.
- (1998) Clin. Infect. Dis. , vol.26 , pp. 1027-1036
- Johnson, S.¹ Gerding, D.N.²

6
- 0028044948
- Clostridium difficile colitis
- DOI 10.1056/NEJM199401273300406
- Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262. (Pubitemid 24034138)
- (1994) New England Journal of Medicine , vol.330 , Issue.4 , pp. 257-262
- Kelly, C.P.¹ Pothoulakis, C.² Lamont, J.T.³

7
- 40549090894
- Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters
- DOI 10.1128/AAC.01143-07
- Kokkotou E, et al. 2008. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob. Agents Chemother. 52:1121-1126. (Pubitemid 351358396)
- (2008) Antimicrobial Agents and Chemotherapy , vol.52 , Issue.3 , pp. 1121-1126
- Kokkotou, E.¹ Moss, A.C.² Michos, A.³ Espinoza, D.⁴ Cloud, J.W.⁵ Mustafa, N.⁶ O'Brien, M.⁷ Pothoulakis, C.⁸ Kelly, C.P.⁹

8
- 38049084783
- Update on the changing epidemiology of Clostridium difficile-associated disease
- McFarland LV. 2008. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 5:40-48.
- (2008) Nat. Clin. Pract. Gastroenterol. Hepatol. , vol.5 , pp. 40-48
- McFarland, L.V.¹

9
- 84855286086
- Clostridium difficile DNA polymerase IIIC: Basis for activity of antibacterial compounds
- Torti A, et al. 2011. Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds. Curr. Enzym. Inhib. 7:147-153.
- (2011) Curr. Enzym. Inhib. , vol.7 , pp. 147-153
- Torti, A.¹

10
- 12444330868
- Active site directed inhibitors of replication-specific bacterial DNA polymerases
- DOI 10.1016/j.bmcl.2004.11.016, PII S0960894X04013526
- Wright GE, et al. 2005. Active site-directed inhibitors of replication-specific bacterial DNA polymerases. Bioorg. Med. Chem. Lett. 15:729-732. (Pubitemid 40143155)
- (2005) Bioorganic and Medicinal Chemistry Letters , vol.15 , Issue.3 , pp. 729-732
- Wright, G.E.¹ Brown, N.C.² Xu, W.-C.³ Long, Z.-Y.⁴ Zhi, C.⁵ Gambino, J.J.⁶ Barnes, M.H.⁷ Butler, M.M.⁸

11
- 79959863108
- 2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity
- 2-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity. Bioorg. Med. Chem. Lett. 21:4197-4202.
- (2011) Bioorg. Med. Chem. Lett. , vol.21 , pp. 4197-4202
- Xu, W.-C.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.